Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

660
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

72.4K
Overview
72.4K
Tissue Transplantation01:24

Tissue Transplantation

519
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
519
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

4.5K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
4.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ALLOPLUS: allogeneic hematopoietic stem cell transplantation in children and adult people living with human immunodeficiency virus, a retrospective study of the SFGM-TC.

Bone marrow transplantation·2026
Same author

A holistic prognostic model for leukemia-free survival after allogeneic transplantation in acute leukemia.

Bone marrow transplantation·2026
Same author

Claudio Bordignon.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

Proof-of-principle 4-marker spatial profiling reveals distinct, location-independent immune clusters in biliary tract cancers.

Pathology oncology research : POR·2026
Same author

Long-term remission of neuromyelitis optica with allogeneic hematopoietic stem cell transplant.

Med (New York, N.Y.)·2026
Same author

Outpatient Rescue With Stem Cells Boost for Refractory Hematotoxicity Following anti-BCMA CAR T-Cell Therapy: A Case Report.

Case reports in hematology·2026

Related Experiment Video

Updated: Sep 10, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.5K

Beyond conventional adoptive T-cell therapy.

Marina Cavazzana1, Juliette Paillet2, Abderrahim Fandi2

  • 1Department of Biotherapy Clinical Investigation Center, AP-HP, Hôpital Necker-Enfants Malades, Paris, France; Smart Immune, Paris, France; Université Paris Cité, Paris; Imagine Institute, Paris.

The Journal of Allergy and Clinical Immunology
|August 23, 2025
PubMed
Summary

Generating human T lymphoid progenitors (HTLPs) via a novel feeder-free system offers a promising approach for T cell deficiencies. This immunotherapy may enhance immune reconstitution after stem cell transplantation.

Keywords:
DLL4Hematopoietic stem cell transplantationT lymphocyteT-cell progenitorimmune reconstitutionlymphopoiesisthymus

More Related Videos

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.3K
Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

14.8K

Related Experiment Videos

Last Updated: Sep 10, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.5K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.3K
Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

14.8K

Area of Science:

  • Immunology
  • Cell Biology
  • Biotechnology

Background:

  • T cell deficiencies compromise immune function and increase risks of infection and relapse, particularly after allogeneic hematopoietic stem cell transplantation for hematological malignancies.
  • Current adoptive T cell therapies face challenges in specificity, safety, scalability, and manufacturing, necessitating alternative strategies for immune reconstitution.

Purpose of the Study:

  • To evaluate the potential of human T lymphoid progenitor (HTLP)-based immunotherapy as a complementary approach to current treatments for T cell deficiencies.
  • To summarize preclinical and clinical research on a novel feeder-free culture system for generating HTLPs and assess its advantages and limitations for immune reconstitution.

Main Methods:

  • Development of a feeder-free culture system using a human DLL4-Fc fusion protein (Notch ligand) to generate HTLPs from CD34+ hematopoietic stem and progenitor cells within 7 days.
  • Characterization of the resulting cell product, ProTcell, identifying key surface markers such as CD7, CCR9, and L-selectin.
  • Assessment of ProTcell's capacity for differentiation and thymic education into T cells following injection into NSG mice.

Main Results:

  • A feeder-free culture system successfully generated HTLPs (ProTcell) from hematopoietic stem and progenitor cells in 7 days.
  • ProTcell comprises cells expressing CD7, CCR9, and L-selectin, indicating lymphoid progenitor identity.
  • In vivo studies demonstrated that injected ProTcell can differentiate and mature into T cells within the thymus of NSG mice.

Conclusions:

  • HTLP-based immunotherapy, generated through the described feeder-free system, presents a viable and potentially advantageous strategy for immune reconstitution in T cell deficiencies.
  • This approach may overcome limitations of current T cell therapies and improve outcomes for patients undergoing stem cell transplantation or suffering from immune disorders.
  • Further preclinical and clinical research is warranted to fully establish the safety, efficacy, and scalability of ProTcell for therapeutic applications.